Atea Pharma Secures $50M Milestone Payment with Roche in the Development of AT-527 for COVID-19

June 17, 2021 Auto Bot License Agreement, Pharma, Roche 0

Shots:

  • Atea Pharma achieved a milestone related to the development of AT-527 and is expecting to receive a related payment of $50M under its license agreement with Roche. The company believes that AT-527 is suitable for use in both pre-and post-exposure prophylactic settings and complementary to vaccines
  • The companies are jointly developing AT-527 for the treatment of COVID-19 where Atea retains commercialization rights for AT-527 in the US and Roche holds the exclusive right to commercialize AT-527 outside of the US
  • AT-527 is currently being evaluated in the global P-III MORNINGSKY trial, P-II study for hospitalized patients with moderate COVID-19, and a P-II outpatient study in patients with mild or moderate COVID-19

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Bain Capital

The post Atea Pharma Secures $50M Milestone Payment with Roche in the Development of AT-527 for COVID-19 first appeared on PharmaShots.